Aprea Therapeutics, Inc. (APRE) Stock Price & Analysis
Aprea Therapeutics, Inc. (APRE) fell 1.49% to USD 0.79 as of September 8, 2026 at 07:35 UTC, according to Nexqual real-time market data.
APRE last closed at USD 0.79; the session ranged USD 0.79–0.81 on volume of 90,483 shares. Market capitalization is —, with a 52-week range of USD 0.55–1.69 (NCM). Source: Nexqual, September 8, 2026 at 07:35 UTC.
Key Statistics (as of September 8, 2026 at 07:35 UTC)
| Price | USD 0.79 |
|---|---|
| Change | ▼ 1.49% (down) |
| Previous Close | USD 0.79 |
| Open | USD 0.79 |
| Day Range | USD 0.79 – 0.81 |
| 52-Week Range | USD 0.55 – 1.69 |
| Volume | 90,483 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (APRE)
Nexqual's technical model rates APRE "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 07:35 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 54.72 (neutral) |
| vs SMA50 | Above (USD 0.72) |
| MACD | 0.04 (positive) |
From Aprea Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.
- If it becomes necessary for us to use patented or proprietary technology of third parties to develop or commercialize our product candidates, we may need to seek a license from such third parties.
- Our approach focuses on matching treatments to specific cancer-related genetic mutations to potentially maximize effectiveness and minimize side effects.
- Our approach is to inhibit these make up genes, thereby specifically killing cancer cells with defined mutations.
Partnerships
- APR-1051 Exhibits Strong Tumor Control in CCNE1-Overexpressing CDX Model In addition, pre-clinical results from an ongoing translational research collaboration with renowned oncology leader MD Anderson Cancer Center support the potential of APR-1051 both as a single agent and in rational immunotherapy combinations in HPV+ head and neck squamous cell carcinoma (HNSCC).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ASMB | Assembly Biosciences, Inc. | USD 36.6 | ▼ 0.33% |
| CYCN | Cyclerion Therapeutics, Inc. | USD 4.25 | ▲ 0% |
| ATXI | Avenue Therapeutics, Inc. | USD 0.54 | ▼ 4.56% |
| BYSI | BeyondSpring, Inc. | USD 0.62 | ▲ 1.16% |
| FULC | Fulcrum Therapeutics, Inc. | USD 3.85 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 07:35 UTC. This page is informational and not investment advice.